| payload |
{"created_at":"2026-04-22T03:03:32.063 {"created_at":"2026-04-22T03:03:32.063787+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:435058b5847bc0db","evidence_event_ids":["evt_60e70e8d17ca"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000021.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000021.txt","company":"Telix Pharmaceuticals Ltd","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000021.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_bfcbc40fed4b90a5","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000021.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:19:49.787488+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000021.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000021.txt","source_event_id":"evt_60e70e8d17ca","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"6-K","fp":"4da1a30dc4f35db5","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-21","2026-04-20","April 21, 2026","April 21, 2026 (Melbourne, Australia)"],"entities":[{"asset_class":"equity","name":"Telix Pharmaceuticals Limited","relevance":"primary","symbol":"","type":"issuer"},{"asset_class":"other","name":"Australian Securities Exchange (ASX)","relevance":"secondary","symbol":"","type":"exchange"},{"asset_class":"other","name":"U.S. Securities and Exchange Commission (SEC)","relevance":"secondary","symbol":"","type":"regulator"},{"asset_class":"other","name":"Christian Krautkramer","relevance":"secondary","symbol":"","type":"signatory"}],"event_type":"listing","information_gaps":["The cleaned text does not include the contents of the attached Exhibit 99.1 beyond the label \u201cASX Announcement \u2013 April 21, 2026\u201d; specific AGM date, agenda items, or proxy details are not provided in the extracted text.","No prior known state is included in the prompt, so the exact \u201cdelta vs prior\u201d cannot be determined from the provided material alone."],"key_facts":["SEC accession number: 0002007191-26-000021 (as shown in the document header).","Form type: 6-K; issuer: Telix Pharmaceuticals Ltd; filed as of date: 2026-04-21; conformed period of report: 2026-04-20 (as shown in header).","The filing states that on April 21, 2026 (Melbourne, Australia), Telix filed an announcement with the ASX titled \u201cTelix Notice of AGM, Proxy Form and Online Guide.\u201d","The ASX announcement is attached to the Form 6-K as Exhibit 99.1 (labeled \u201cASX Announcement \u2013 April 21, 2026\u201d).","The Form 6-K includes signatures and is signed by Christian Krautkramer, Group General Counsel, dated April 21, 2026."],"numeric_claims":[{"label":"Exhibit number","value":"99.1"},{"label":"Form filing date (as of date)","value":"2026-04-21"},{"label":"Conformed period of report","value":"2026-04-20"}],"primary_claim":"On April 21, 2026, Telix filed an ASX announcement titled \u201cTelix Notice of AGM, Proxy Form and Online Guide,\u201d and included it as Exhibit 99.1 to its Form 6-K.","relevance_score":0.35,"sentiment":"neutral","source_quality":"high","summary":"Telix Pharmaceuticals Ltd filed a Form 6-K on April 21, 2026 reporting that it filed an announcement with the Australian Securities Exchange on April 21, 2026 titled \u201cTelix Notice of AGM, Proxy Form and Online Guide,\u201d attached as Exhibit 99.1.","topics":["Form 6-K","AGM notice","proxy form","online guide","Exhibit 99.1","foreign private issuer reporting"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 6-K \u00b7 Telix Pharmaceuticals Ltd \u00b7 Filed 20260421","ticker":"TLX","tickers":["TLX"],"title":"TLX filed 6-K","url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000021.txt"}}... |